Anidulafungin is commonly used across conditions presenting with acute or disruptive symptom patterns, applied in contexts where additional symptomatic support is needed. It is indicated for managing serious systemic fungal infections.

The treatment is commonly used to help with the process of microbiological clearance of the pathogen, which may assist in addressing acute, systemic symptoms like persistent fever and circulatory instability associated with fungal sepsis. The medication is applied in addressing invasive candidiasis, which includes candidemia (bloodstream infection), as well as deep-seated infections like peritonitis and intra-abdominal abscesses.

The medication is considered relevant for symptomatic support for both adults and younger patients (infants and older). It is also commonly used to help with managing esophageal candidiasis in adults or infections caused by Candida strains suspected to be resistant to azole antifungals.

“It is a key treatment for serious fungal infections, providing necessary support during periods of heightened physiological stress.”

Quick Fact: Relief for Fungal Sepsis Indicators

The overall use supports general well-being during symptomatic phases and may contribute to improved comfort when symptoms become more noticeable.

Contraindications and Absolute Exclusions

The use of Anidulafungin is strictly contraindicated for specific populations as defined by regulatory authorities. The medicine must not be used by patients with a known hypersensitivity to anidulafungin, any component of the formulation, or to any other medicine belonging to the echinocandin class. Furthermore, use is prohibited for individuals with known or suspected Hereditary Fructose Intolerance (HFI), a restriction related to the fructose content in the product's excipients.

Age-Related Eligibility and Limitations

Anidulafungin is approved for use in adults and older adults without requiring age-based dosage adjustments. The medicine is also approved for pediatric patients from 1 month to under 18 years of age. However, use in neonates (patients younger than 1 month) is generally not recommended, as safety and effectiveness have not been established in that age group.

Conditional Use and Organ Function

Regulatory labeling establishes that patients with any degree of renal impairment or hepatic impairment (including mild, moderate, or severe) are eligible for use with no dosage adjustment required. Restrictions apply to pregnant women: use is not recommended unless the potential benefit clearly outweighs the potential risk. Breastfeeding women are advised to discontinue nursing or the therapy due to unknown excretion into human milk. The medicine has also not been studied in specific populations with Candida infections such as endocarditis or osteomyelitis.

Interactions with other medicines and products

Official Pharmacokinetic Interaction Profile

Anidulafungin has a distinct interaction profile largely due to its clearance pathway. The drug is not a clinically relevant substrate, inhibitor, or inducer of the Cytochrome P450 (CYP450) enzyme system, minimizing the risk of many typical pharmacokinetic drug–drug interactions.

Regulatory studies have formally confirmed the absence of clinically significant pharmacokinetic interaction when Anidulafungin is co-administered with several high-risk medicines. The steady-state plasma concentrations of Anidulafungin and the co-administered drug were not substantially altered for the following agents, resulting in no required dosage adjustment:

• Cyclosporine
• Voriconazole
• Tacrolimus
• Rifampin
• Amphotericin B Liposome

---

Other Documented Restrictions and Considerations

Interaction Type	Official Regulatory Statement
Population-Specific	Hepatic and Renal Impairment: No dosage adjustment is required for patients with mild, moderate, or severe hepatic impairment or for any degree of renal insufficiency, including those on hemodialysis.
Product-Excipient	Fructose Intolerance: The medicine is restricted for use in patients with documented hereditary fructose intolerance (HFI) due to the presence of fructose excipients in the formulation.
Product-Supplement	Systemic antifungals may diminish the therapeutic effect of the probiotic Saccharomyces boulardii (Brewer's Yeast).

Anidulafungin is a member of the echinocandin class that exerts its effect through selective molecular interaction within the fungal cell. Its primary biological target is the enzyme beta-(1,3)-D-glucan synthase. This enzyme is structurally distinct to fungal organisms and is responsible for synthesizing beta-(1,3)-D-glucan, a major polysaccharide component essential for the structural integrity and resilience of the fungal cell wall.

The interaction type is characterized by noncompetitive inhibition of the enzyme. This pathway modulation results in the immediate cessation of beta-(1,3)-D-glucan formation, which creates a severe structural deficit in the fungal cell wall. The mechanistic cascade involves the rapid compromise of cell wall rigidity, making the cell highly vulnerable to internal osmotic pressure. The system-level physiological consequence on the pathogen is cell lysis, culminating in the death of the fungal cell.

Anidulafungin is supplied as a lyophilized powder for concentrate for solution for infusion and must be administered exclusively via the intravenous (IV) route. It is a once-daily regimen that begins with a higher initial dose to ensure rapid systemic concentration, followed by a lower maintenance dose thereafter.

Official Adult Dosing Regimens

The standard adult dosing protocol involves an initial dose on Day 1, followed by a maintenance dose once daily. The exact doses differ based on the type of systemic infection being addressed:

• For Invasive Candida Infections: A single 200 mg loading dose is administered on Day 1, followed by a 100 mg once-daily maintenance dose.
• For Esophageal Candidiasis: A single 100 mg loading dose is administered on Day 1, followed by a 50 mg once-daily maintenance dose.

Administration and Procedural Rules

Administration must follow strict procedural steps: the powder is first reconstituted with sterile water for injection and then diluted with an authorized IV solution (e.g., 0.9% Sodium Chloride) prior to infusion. The final solution must not be administered as a bolus injection, and the infusion rate must not exceed 1.1 mg/minute. The medicine may be given without regard to food intake or the timing of hemodialysis.

Duration and Population Use

Treatment duration is typically based on the patient's response and is generally continued for at least 14 days after the last positive culture has been reported. For pediatric patients (1 month to less than 18 years), dosing is calculated based on body weight, using a 3.0 mg/kg loading dose (max 200 mg) and a 1.5 mg/kg daily maintenance dose (max 100 mg). No dose adjustment is required for adult patients with any degree of renal or hepatic impairment.

Anidulafungin: Recent Clinical Evidence

Overview of Studies

Anidulafungin, an echinocandin antifungal agent, is indicated for the treatment of invasive candidiasis (IC), including candidemia. Clinical evidence focuses primarily on its use in adult patients and its comparison with other antifungal treatments.

Studies investigated the compound's effect on the fungal cell wall, specifically by non-competitively inhibiting the synthesis of beta-(1,3)-D-glucan, an essential component of the cell wall of most Candida species. This action leads to structural instability and cell death.

Key Findings

Comparative Effectiveness

Randomized, controlled trials (RCTs) have evaluated anidulafungin against fluconazole, a standard azole treatment, for IC. A large meta-analysis examined various studies and reported that anidulafungin was associated with a favorable outcome compared to fluconazole in treating IC, particularly in certain patient subgroups, such as those with severe illness or specific Candida species infections. Primary endpoints often included all-cause mortality and treatment success at the end of intravenous therapy (Day 10 or 14).

Use in Specific Populations

Research has explored the use of anidulafungin in patients with underlying conditions, such as neutropenia or hepatic impairment. Data suggest that dose adjustment is generally not required for patients with mild-to-moderate hepatic impairment due to its minimal hepatic metabolism. Studies have also investigated its role as a step-down therapy after initial broad-spectrum antifungal agents.

Safety and Tolerability

Clinical trials reported that anidulafungin is generally well-tolerated. Common adverse events reported in studies were typically mild or moderate in severity and included diarrhea, nausea, vomiting, and increases in liver enzyme levels (ALT and AST). Unlike some other antifungals, anidulafungin exhibits minimal drug-drug interactions, a factor studied for its use in critically ill patients receiving multiple medications.

Key Studies & References ERAXIS (anidulafungin) for Injection, for intravenous use: US Prescribing Information

Common questions about Anidulafungin (FAQ)

---

Q: What are the main types of infections Anidulafungin is approved to treat?

Anidulafungin is indicated for the treatment of serious systemic fungal infections. This includes candidemia and other forms of invasive Candida infections, which can affect deep tissues and organs. The medicine is also officially approved for treating esophageal candidiasis.

---

Q: Is Anidulafungin used to treat fungal infections in the brain or central nervous system?

Official product information indicates that Anidulafungin has not been studied in patients with infections of the Central Nervous System (CNS), such as meningitis. Therefore, information on whether the medicine effectively penetrates the CNS is not available in regulatory documents.

---

Q: Is hair loss or alopecia a reported side effect of Anidulafungin?

Official regulatory documents, which classify adverse events based on clinical trials, do not list alopecia (hair loss) as either a common or uncommon side effect associated with Anidulafungin.

---

Q: Can Anidulafungin cause changes in sleep patterns?

Official product summaries report that trouble sleeping (insomnia) is a possible side effect that may occur while receiving this medicine.

---

Q: Does Anidulafungin affect blood pressure?

Hypotension, or low blood pressure, is listed in regulatory documents as a potential adverse reaction. This effect is specifically noted in connection with infusion-related events.

---

Q: Is Anidulafungin known by other brand names besides Eraxis?

Yes, the active ingredient Anidulafungin is marketed under the brand name Eraxis in some regions and is also sold under the brand name Ecalta in others.

---

Q: Does Anidulafungin interact with common pain relievers or over-the-counter medicines?

Official pharmacokinetic studies indicate that Anidulafungin does not significantly affect the CYP450 enzyme system, which processes many medications. This mechanism minimizes the risk of many typical drug-drug interactions; however, specific over-the-counter pain relievers are not individually assessed.

---

Q: Is there a concern about using Anidulafungin while taking HIV antiretroviral therapy?

Regulatory studies confirmed no clinically significant pharmacokinetic interaction with certain high-risk drugs, including immunosuppressants like Cyclosporine and Tacrolimus. However, official information does not provide a general statement regarding all medications used in HIV antiretroviral therapy.

---

Q: Does Anidulafungin interact with food or specific dietary supplements?

The medicine can be given without regard to food intake. Official warnings note that the medicine may diminish the therapeutic effect of the probiotic Saccharomyces boulardii (Brewer's Yeast). Additionally, due to its composition, the medicine is strictly prohibited for use in patients with hereditary fructose intolerance (HFI).

---

Q: Is there official information on whether Anidulafungin passes into breast milk?

Official product information states it is unknown whether the drug is excreted in human milk, though animal studies have shown excretion. The official product label states that a decision should be made whether to discontinue nursing or discontinue the therapy, taking into account the potential benefits and risks.

---

Q: How is Anidulafungin broken down by the body since very little is excreted by the kidneys?

Anidulafungin is primarily eliminated through a process called non-enzymatic hydrolysis, which is a slow chemical degradation that occurs naturally in the body. This process transforms the medicine into a compound that is no longer antifungal. Very little of the medicine is removed by the kidneys.

---

Q: What general guidance is provided if a dose of Anidulafungin is missed?

According to patient information, guidance for a missed dose is generally to administer it as soon as the dose is remembered. However, if it is almost time for the next scheduled dose, the missed dose is generally skipped, and the regular dosing schedule is resumed.

---

Q: Is it possible for the fungal infection to relapse after Anidulafungin treatment is finished?

Regulatory documents note that there can be a risk of the infection returning (relapse) after treatment, particularly for esophageal candidiasis in certain patient groups. For this reason, additional suppressive antifungal therapy may be considered following the initial course of treatment.

---

Q: Has Anidulafungin been studied for preventing fungal infections in high-risk patients?

The drug is officially indicated for the treatment of established fungal infections. While official documents note that its use has been explored in specific high-risk patient groups, such as those with neutropenia, it is not officially labeled for preventing infections (prophylaxis).

---

Q: What are the general storage requirements for Anidulafungin vials before they are prepared for infusion?

The unopened vials of dry powder must be kept refrigerated at a temperature between 2 C to 8 C (36 F to 46 F). It is crucial that the vials are not frozen to maintain the stability of the medicine.

---

Q: What should a patient or caregiver look for in the medicine before it is infused (e.g., discoloration, particles)?

Official instruction is that the final diluted solution is inspected by a medical professional or caregiver prior to administration. Regulatory documents specify that the solution is not to be used if it appears discolored or if any particles are visible in the liquid.

The official storage and disposal requirements for Anidulafungin (lyophilized powder for concentrate for infusion) are defined by government regulatory documents to ensure product stability and safety.

Storage Conditions

Product Stage	Required Temperature	Stability/Time Limit
Unreconstituted Vial	2 C to 8 C (Refrigerated)	Must not be frozen.
Final Infusion Solution	At or below 25 C (Room Temp)	48 hours maximum.

Unopened vials must be stored in a refrigerator and kept in the original container for light protection. A single temperature excursion up to 25 C is permitted for up to 96 hours. Both the reconstituted concentrate and the final infusion solution must not be frozen.

Disposal and Handling

Used needles and syringes must be immediately placed into a puncture-resistant sharps disposal container. All disposal of the drug and related materials must strictly comply with federal, state, and local regulations for pharmaceutical waste. The drug product and all disposal containers must be kept out of the sight and reach of children and pets.